Differentiated thyroid cancer shows a comparable prognosis in patients with immunocompromised vs immunocompetent status, a ...
The FDA has granted fast track designation to zotiraciclib (TG02), an oral central nervous sytem-penetrant multikinase inhibitor, for treatment of patients with recurrent high-grade gliomas (rHGG) ...
Che-Kai Tsao, MD, MS, system chief of Solid Tumor Oncology at Northwell Health Cancer Institute, discusses new approaches that could change the standard of care for metastatic hormone-sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback